Home News

News

ESMO 2020: Study Shows Meaningful Clinical Activity with Tisotumab Vedotin in Cervical Cancer

Tisotumab vedotin, an investigational agent is being developed by Seattle Genetics and Genmab, shows meaningful clinical activity as monotherapy...

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27% ORR

Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunimedics).This is the conclusion from an analysis...

Study Meets Primary Endpoint: Enfortumab Vedotin Significantly Improves Overall Survival in Urothelial Cancer

A phase III trial of enfortumab vedotin (enfortumab vedotin-ejfv; Padcev®; Seattle Genetics/Astellas) met its primary endpoint of overall survival...
ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain Cancer

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the...

ESMO 2020: XMT-1536 Shows 34% ORR in Phase I Expansion Study in Ovarian Cancer

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the...

In vivo data Shows Efficacy of Synaffix’ Proprietary Exatecan Linker-Payload to be on par...

In a poster presented during the virtual World ADC meeting, being held September 15 - 17, 2020 scientists at...

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in HER3 Expressing Advanced...

A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as...

Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development Agreement

Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize...
Scientist pipetting

Gilead Acquires Immunomedics – Accelerating an Emerging and Complementary Oncology Pipeline

Just ahead of World ADC, the industry meeting for anyone involved in the development, manufacturing antibody-drug conjugates, and the...

Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced Solid Tumors

Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online...